Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Cash & Equivalents (2017 - 2025)

Inspire Medical Systems' Cash & Equivalents history spans 9 years, with the latest figure at $104.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 30.19% year-over-year to $104.8 million; the TTM value through Dec 2025 reached $104.8 million, down 30.19%, while the annual FY2025 figure was $104.8 million, 30.19% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $104.8 million at Inspire Medical Systems, down from $112.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $467.1 million in Q2 2023 and bottomed at $53.9 million in Q1 2025.
  • The 5-year median for Cash & Equivalents is $186.1 million (2022), against an average of $224.9 million.
  • The largest annual shift saw Cash & Equivalents surged 150.34% in 2023 before it plummeted 69.28% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $214.5 million in 2021, then skyrocketed by 105.9% to $441.6 million in 2022, then plummeted by 57.98% to $185.5 million in 2023, then dropped by 19.07% to $150.2 million in 2024, then tumbled by 30.19% to $104.8 million in 2025.
  • Per Business Quant, the three most recent readings for INSP's Cash & Equivalents are $104.8 million (Q4 2025), $112.8 million (Q3 2025), and $106.9 million (Q2 2025).